SCHEMBL10249343

SCHEMBL10249343

Cc1ccc2c(c1)nc(-c1ccncc1SCC#N)n2C

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TSHR P16473 2/20 0.42
▸ ALOX15 P16050 1/20 0.42
▸ L3MBTL1 Q9Y468 1/20 0.42
▸ SMN1; SMN2 Q16637 3/20 0.40
▸ POLB P06746 2/20 0.40
▸ PDE10A Q9Y233 2/20 0.39
▸ LMNA P02545 2/20 0.37
▸ CA12 O43570 1/20 0.37
▸ CA1 P00915 1/20 0.37
▸ CA2 P00918 1/20 0.37
▸ CA9 Q16790 1/20 0.37
▸ CA14 Q9ULX7 1/20 0.37
▸ AGPAT2 O15120 2/20 0.36
▸ ATM Q13315 1/20 0.36
▸ KDM4E B2RXH2 2/20 0.36
▸ HSD17B10 Q99714 2/20 0.36
▸ HPGD P15428 2/20 0.36
▸ MAPK1 P28482 2/20 0.36
▸ MAPT P10636 3/20 0.36
▸ NPC1 O15118 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10249144 0.89 SMN1; SMN2 (0.38) TSHRALOX15L3MBTL1SMN1; SMN2POLB
SCHEMBL10249306 0.89 SMN1; SMN2 (0.40) SMN1; SMN2POLBPDE10ALMNACA12
SCHEMBL10284947 0.86 PDE10A (0.43) TSHRSMN1; SMN2POLBPDE10ACA12
SCHEMBL10248957 0.86 SMN1; SMN2 (0.43) SMN1; SMN2POLBPDE10ALMNAAGPAT2
SCHEMBL10249282 0.83 TSHR (0.36) TSHRALOX15L3MBTL1SMN1; SMN2POLB
SCHEMBL10249110 0.83 SMN1; SMN2 (0.40) SMN1; SMN2POLBPDE10ALMNAAGPAT2
SCHEMBL10252630 0.82 POLB (0.40) TSHRL3MBTL1SMN1; SMN2POLBPDE10A
SCHEMBL10249150 0.82 TLR8 (0.41) SMN1; SMN2POLBPDE10ALMNAAGPAT2
SCHEMBL10249017 0.82 MAPT (0.40) SMN1; SMN2POLBPDE10ALMNAAGPAT2
SCHEMBL10248930 0.82 SMN1; SMN2 (0.45) SMN1; SMN2POLBPDE10ALMNACA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8461181-B2 Fused heterocyclic compound and use thereof SUMITOMO CHEMICAL COMPANY, LTD. (JP) 2013-06-11 — — US disclosed
US-8273764-B2 Fused heterocyclic compounds and use thereof SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2012-09-25 — — US disclosed
US-20120178779-A1 FUSED HETEROCYCLIC COMPOUND AND USE THEREOF SUMITOMO CHEMICAL COMPANY, LIMITED 2012-07-12 — — US disclosed
US-20120015975-A1 FUSED HETEROCYCLIC COMPOUND AND USE THEREOF SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2012-01-19 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120178779-A1 FUSED HETEROCYCLIC COMPOUND AND USE THEREOF C3AR1, C9, C5 TSHR 396/4885ALOX15 2102/4885L3MBTL1 13/4885
US-20120015975-A1 FUSED HETEROCYCLIC COMPOUND AND USE THEREOF C3AR1, C9, C5 TSHR 396/4885ALOX15 2102/4885L3MBTL1 13/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback